vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.